ECSP088633A - Compuestos miméticos de lisina modificados - Google Patents
Compuestos miméticos de lisina modificadosInfo
- Publication number
- ECSP088633A ECSP088633A EC2008008633A ECSP088633A ECSP088633A EC SP088633 A ECSP088633 A EC SP088633A EC 2008008633 A EC2008008633 A EC 2008008633A EC SP088633 A ECSP088633 A EC SP088633A EC SP088633 A ECSP088633 A EC SP088633A
- Authority
- EC
- Ecuador
- Prior art keywords
- lisine
- modified
- mimetic compounds
- mimetic
- compounds
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C233/00—Carboxylic acid amides
- C07C233/64—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings
- C07C233/81—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/04—Drugs for disorders of the respiratory system for throat disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/04—Drugs for genital or sexual disorders; Contraceptives for inducing labour or abortion; Uterotonics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
- A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C233/00—Carboxylic acid amides
- C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
- C07C233/30—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by doubly-bound oxygen atoms
- C07C233/31—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by doubly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C233/00—Carboxylic acid amides
- C07C233/57—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of rings other than six-membered aromatic rings
- C07C233/61—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of rings other than six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by doubly-bound oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C233/00—Carboxylic acid amides
- C07C233/64—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings
- C07C233/81—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups
- C07C233/82—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom
- C07C233/83—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom of an acyclic saturated carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
- C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
- C07C237/20—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton containing six-membered aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
- C07C237/24—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a ring other than a six-membered aromatic ring of the carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
- C07C237/28—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton
- C07C237/30—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton having the nitrogen atom of the carboxamide group bound to hydrogen atoms or to acyclic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
- C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
- C07D407/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06008—Dipeptides with the first amino acid being neutral
- C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
- C07K5/06026—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atom, i.e. Gly or Ala
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Diabetes (AREA)
- Cardiology (AREA)
- Physical Education & Sports Medicine (AREA)
- Hematology (AREA)
- Heart & Thoracic Surgery (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Rheumatology (AREA)
- Urology & Nephrology (AREA)
- Obesity (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pulmonology (AREA)
- Gynecology & Obstetrics (AREA)
- Pain & Pain Management (AREA)
- Biochemistry (AREA)
- Hospice & Palliative Care (AREA)
- Toxicology (AREA)
- Vascular Medicine (AREA)
- Pregnancy & Childbirth (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
Abstract
Se proporcionan Compuestos miméticos de lisina que tienen actividad farmacológica útil tal como actividad antiarrítmica y propiedades beneficiosas de biodisponibilidad
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US75362805P | 2005-12-23 | 2005-12-23 |
Publications (1)
Publication Number | Publication Date |
---|---|
ECSP088633A true ECSP088633A (es) | 2008-09-29 |
Family
ID=38110525
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EC2008008633A ECSP088633A (es) | 2005-12-23 | 2008-07-18 | Compuestos miméticos de lisina modificados |
Country Status (27)
Country | Link |
---|---|
US (4) | US7622496B2 (es) |
EP (2) | EP2386539B1 (es) |
JP (1) | JP5473334B2 (es) |
KR (1) | KR101397915B1 (es) |
CN (2) | CN102690221B (es) |
AR (1) | AR058748A1 (es) |
AU (1) | AU2006332945C1 (es) |
BR (1) | BRPI0620436B8 (es) |
CA (1) | CA2634743C (es) |
CR (1) | CR10089A (es) |
DK (1) | DK1966130T3 (es) |
EC (1) | ECSP088633A (es) |
ES (1) | ES2443242T3 (es) |
GT (1) | GT200800123A (es) |
HK (1) | HK1121438A1 (es) |
HN (1) | HN2008000957A (es) |
IL (1) | IL192395A (es) |
NZ (1) | NZ569293A (es) |
PE (1) | PE20070849A1 (es) |
PL (1) | PL1966130T3 (es) |
PT (1) | PT1966130E (es) |
RU (1) | RU2494095C2 (es) |
SG (1) | SG170767A1 (es) |
SI (1) | SI1966130T1 (es) |
TW (1) | TWI411597B (es) |
UA (1) | UA96283C2 (es) |
WO (1) | WO2007078990A2 (es) |
Families Citing this family (35)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PT1966130E (pt) * | 2005-12-23 | 2014-01-30 | Zealand Pharma As | Compostos miméticos de lisina modificados |
US20080188545A1 (en) * | 2006-12-21 | 2008-08-07 | Alimardanov Asaf R | Synthesis of pyrrolidine compounds |
US20100298225A1 (en) * | 2007-07-15 | 2010-11-25 | Bjarne Due Larsen | Peptide gap junction modulators |
US8377968B2 (en) | 2008-06-02 | 2013-02-19 | Zalicus Pharmaceuticals, Ltd. | N-piperidinyl acetamide derivatives as calcium channel blockers |
WO2011032291A1 (en) * | 2009-09-18 | 2011-03-24 | Zalicus Pharmaceuticals Ltd . | Selective calcium channel modulators |
EP2804605A4 (en) * | 2012-01-20 | 2015-07-08 | Acucela Inc | SUBSTITUTED HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF DISEASES |
WO2014134306A1 (en) | 2013-03-01 | 2014-09-04 | Zalicus Pharmaceuticals, Ltd. | Heterocyclic inhibitors of the sodium channel |
CN105188694B (zh) | 2013-03-15 | 2018-07-31 | 卓莫赛尔公司 | 用于治疗疼痛的钠通道调节剂 |
CA2922851C (en) * | 2013-09-10 | 2023-03-14 | Chromocell Corporation | Sodium channel modulators for the treatment of pain and diabetes |
US10010541B2 (en) | 2014-01-30 | 2018-07-03 | The Board Of Trustees Of The Leland Stanford Junior University | Modulation of tissue transglutaminase activation in disease |
KR20160127025A (ko) * | 2014-02-28 | 2016-11-02 | 히칼 리미티드 | 빌다글립틴의 신규하고 경제적인 제조 |
DK3618847T3 (da) | 2017-05-05 | 2021-05-25 | Boston Medical Ct Corp | GAP-junction-modulatorer af intercellulær kommunikation og deres anvendelse til behandling af diabetisk øjensygdom |
WO2019028362A1 (en) * | 2017-08-04 | 2019-02-07 | Dyax Corp. | INHIBITORS OF PLASMATIC KALLIKREIN AND USES THEREOF |
CR20200054A (es) | 2017-08-09 | 2020-03-21 | Denali Therapeutics Inc | Compuestos, composiciones y métodos |
JP7366031B2 (ja) | 2017-09-22 | 2023-10-20 | カイメラ セラピューティクス, インコーポレイテッド | タンパク質分解剤およびそれらの使用 |
WO2019060693A1 (en) | 2017-09-22 | 2019-03-28 | Kymera Therapeutics, Inc. | CRBN LIGANDS AND USES THEREOF |
JP2021508703A (ja) | 2017-12-26 | 2021-03-11 | カイメラ セラピューティクス, インコーポレイテッド | Irak分解剤およびそれらの使用 |
EP3737666A4 (en) | 2018-01-12 | 2022-01-05 | Kymera Therapeutics, Inc. | PROTEIN DEGRADANTS AND USES THEREOF |
WO2019140387A1 (en) | 2018-01-12 | 2019-07-18 | Kymera Therapeutics, Inc. | Crbn ligands and uses thereof |
US11292792B2 (en) | 2018-07-06 | 2022-04-05 | Kymera Therapeutics, Inc. | Tricyclic CRBN ligands and uses thereof |
KR20210111252A (ko) | 2018-11-30 | 2021-09-10 | 카이메라 쎄라퓨틱스 인코포레이티드 | Irak 분해제 및 이의 용도 |
CA3129609A1 (en) | 2019-02-13 | 2020-08-20 | Denali Therapeutics Inc. | Eukaryotic initiation factor 2b modulators |
WO2020206424A1 (en) | 2019-04-05 | 2020-10-08 | Kymera Therapeutics, Inc. | Stat degraders and uses thereof |
CN112142823B (zh) * | 2019-06-28 | 2022-08-05 | 深圳翰宇药业股份有限公司 | 一种zp-1609的合成方法 |
EP3989966A4 (en) | 2019-06-28 | 2023-09-27 | Kymera Therapeutics, Inc. | IRAQ DEGRADERS AND USES THEREOF |
TW202116314A (zh) | 2019-07-11 | 2021-05-01 | 美商普雷西斯精密藥品公司 | T型鈣離子通道調節劑之調配物及其使用方法 |
EP4076524A4 (en) | 2019-12-17 | 2023-11-29 | Kymera Therapeutics, Inc. | IRAQ DEGRADERS AND USES THEREOF |
TW202136251A (zh) | 2019-12-17 | 2021-10-01 | 美商凱麥拉醫療公司 | Irak降解劑及其用途 |
BR112022012410A2 (pt) | 2019-12-23 | 2022-08-30 | Kymera Therapeutics Inc | Degradadores smarca e usos dos mesmos |
IL296451A (en) | 2020-03-19 | 2022-11-01 | Kymera Therapeutics Inc | mdm2 joints and their uses |
TW202210483A (zh) | 2020-06-03 | 2022-03-16 | 美商凱麥拉醫療公司 | Irak降解劑之結晶型 |
WO2022120355A1 (en) | 2020-12-02 | 2022-06-09 | Ikena Oncology, Inc. | Tead degraders and uses thereof |
WO2022171525A1 (en) | 2021-02-10 | 2022-08-18 | Ciana Therapeutics Aps | Danegaptide for use in the treatment or prevention of a kidney disease |
CA3236262A1 (en) | 2021-10-25 | 2023-05-04 | Isaac Marx | Tyk2 degraders and uses thereof |
WO2023118366A1 (en) | 2021-12-22 | 2023-06-29 | Breye Therapeutics Aps | Gap junction modulators and their use for the treatment of age-related macular degeneration |
Family Cites Families (76)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE1125587B (de) * | 1957-03-06 | 1962-03-15 | Schering Ag | Roentgenkontrastmittel |
ZA817601B (en) * | 1980-11-24 | 1982-10-27 | Squibb & Sons Inc | Carboxyalkyl amino acid derivatives of various substituted prolines |
US4462943A (en) | 1980-11-24 | 1984-07-31 | E. R. Squibb & Sons, Inc. | Carboxyalkyl amino acid derivatives of various substituted prolines |
CA1276392C (en) | 1981-08-03 | 1990-11-13 | Donald S. Karanewsky | Phosphonamidate compounds |
EP0088350B1 (en) | 1982-03-08 | 1985-02-20 | Schering Corporation | Carboxyalkyl dipeptides, processes for their production and pharmaceutical compositions containing them |
US4514391A (en) | 1983-07-21 | 1985-04-30 | E. R. Squibb & Sons, Inc. | Hydroxy substituted peptide compounds |
US5684016A (en) * | 1984-04-12 | 1997-11-04 | Hoechst Aktiengesellschaft | Method of treating cardiac insufficiency |
US4560506A (en) | 1984-05-25 | 1985-12-24 | E. R. Squibb & Sons, Inc. | Mercaptocycloalkylcarbonyl and mercaptoarylcarbonyl dipeptides |
ATE135711T1 (de) * | 1984-09-12 | 1996-04-15 | Rhone Poulenc Rorer Pharma | Antihypertensive derivate |
US4746676A (en) * | 1984-09-12 | 1988-05-24 | Rorer Pharmaceutical Corporation | Carboxyalkyl dipeptide compounds |
JPS61148198A (ja) * | 1984-12-22 | 1986-07-05 | Ajinomoto Co Inc | 新規トリペプチド化合物および甘味剤 |
JPS6259296A (ja) | 1985-09-10 | 1987-03-14 | Green Cross Corp:The | ペプタイド誘導体 |
EP0254032A3 (en) | 1986-06-20 | 1990-09-05 | Schering Corporation | Neutral metalloendopeptidase inhibitors in the treatment of hypertension |
EP0566157A1 (en) | 1986-06-20 | 1993-10-20 | Schering Corporation | Neutral metalloendopeptidase inhibitors in the treatment of hypertension |
US4849525A (en) | 1987-09-21 | 1989-07-18 | E. R. Squibb & Sons, Inc. | Phosphinylcycloalkylcarbonyl and phosphinylcycloalkenylcarbonyl dipeptides |
US5120859A (en) * | 1989-09-22 | 1992-06-09 | Genentech, Inc. | Chimeric amino acid analogues |
FR2700166B1 (fr) * | 1993-01-07 | 1995-02-17 | Rhone Poulenc Rorer Sa | Dérivés de pyrrolidine, leur préparation et les médicaments les contenant. |
CZ134296A3 (en) | 1993-11-09 | 1996-12-11 | Merck & Co Inc | Piperidine, pyrrolidine and hexahydro-1h-azepine derivatives, process of their preparation and pharmaceutical compositions containing thereof |
DE4408531A1 (de) | 1994-03-14 | 1995-09-28 | Hoechst Ag | PNA-Synthese unter Verwendung einer gegen schwache Säuren labilen Amino-Schutzgruppe |
GB9409150D0 (en) | 1994-05-09 | 1994-06-29 | Black James Foundation | Cck and gastrin receptor ligands |
JPH0892207A (ja) * | 1994-07-26 | 1996-04-09 | Sankyo Co Ltd | ピロリジン誘導体 |
US5491164A (en) | 1994-09-29 | 1996-02-13 | Merck & Co., Inc. | Inhibitors of farnesyl-protein transferase |
WO1997036873A1 (en) | 1996-04-03 | 1997-10-09 | Merck & Co., Inc. | Piperidines, pyrrolidines and hexahydro-1h-azepines promote release of growth hormone |
DE69716449T2 (de) | 1996-08-28 | 2003-08-07 | Procter & Gamble | Substituierte zyklische amine als metalloproteaseinhibitoren |
WO1998011125A1 (en) | 1996-09-09 | 1998-03-19 | Zealand Pharmaceuticals A/S | Improved solid-phase peptide synthesis and agent for use in such synthesis |
AU4342097A (en) | 1996-09-13 | 1998-04-02 | Merck & Co., Inc. | Piperidines, pyrrolidines and hexahydro-1h-azepines promote release of growth hormone |
UA66767C2 (uk) * | 1996-10-18 | 2004-06-15 | Вертекс Фармасьютикалс Інкорпорейтед | Інгібітори серин-протеаз, фармацевтична композиція, спосіб інгібування активності та спосіб лікування або профілактики вірусної інфекції гепатиту с |
JP4024309B2 (ja) * | 1996-10-22 | 2007-12-19 | 第一三共株式会社 | 新規な感染症治療薬 |
WO1998025897A1 (en) | 1996-12-12 | 1998-06-18 | Merck & Co., Inc. | Piperidines, pyrrolidines and hexahydro-1h-azepines promote release of growth hormone |
EP1021190B1 (en) | 1997-08-22 | 2006-11-08 | Kaken Pharmaceutical Co., Ltd. | Amid derivatives as growth hormone release promotors |
US6399629B1 (en) * | 1998-06-01 | 2002-06-04 | Microcide Pharmaceuticals, Inc. | Efflux pump inhibitors |
RU2243214C2 (ru) * | 1998-06-04 | 2004-12-27 | Астразенека Аб | Новые производные и аналоги 3-арилпропионовой кислоты |
US6426331B1 (en) * | 1998-07-08 | 2002-07-30 | Tularik Inc. | Inhibitors of STAT function |
US6242422B1 (en) | 1998-10-22 | 2001-06-05 | Idun Pharmacueticals, Inc. | (Substituted)Acyl dipeptidyl inhibitors of the ice/ced-3 family of cysteine proteases |
IL147495A0 (en) | 1999-07-28 | 2002-08-14 | Aventis Pharm Prod Inc | Substituted oxoazaheterocycclyl compounds |
ATE324876T1 (de) | 1999-10-14 | 2006-06-15 | Curis Inc | VERMITTLER VON ßHEDGEHOGß ÜBERMITTELNDEN BAHNEN, DAZUGEHÖRIGE ZUSAMMENETZUNGEN UND VERWENDUNGEN |
US6552016B1 (en) | 1999-10-14 | 2003-04-22 | Curis, Inc. | Mediators of hedgehog signaling pathways, compositions and uses related thereto |
WO2001034594A1 (en) | 1999-11-12 | 2001-05-17 | Guilford Pharmaceuticals, Inc. | Dipeptidyl peptidase iv inhibitors and methods of making and using dipeptidyl peptidase iv inhibitors |
PT1226160E (pt) | 2000-02-23 | 2005-04-29 | Zealand Pharma As | Novos peptidos antiarritmicos |
WO2002077017A2 (en) | 2001-02-22 | 2002-10-03 | Zealand Pharma A/S | Medical uses of intercellular communication facilitating compounds |
CA2404314A1 (en) | 2000-03-31 | 2001-10-11 | Lorin Andrew Thompson | Succinoylamino heterocycles as inhibitors of a.beta. protein production |
AU2001253633A1 (en) | 2000-04-17 | 2001-10-30 | Idun Pharmaceuticals, Inc. | Inhibitors of the ice/ced-3 family of cysteine proteases |
AU2000249828A1 (en) | 2000-05-03 | 2001-11-12 | Taisho Pharmaceutical Co. Ltd. | Stat4 and stat6 binding dipeptide derivatives |
IL153115A0 (en) | 2000-06-16 | 2003-06-24 | Curis Inc | Angiogenesis-modulating compositions and uses |
EP1301527A2 (en) | 2000-07-21 | 2003-04-16 | Corvas International, Inc. | Peptides as ns3-serine protease inhibitors of hepatitis c virus |
SI1385870T1 (sl) | 2000-07-21 | 2010-08-31 | Schering Corp | Peptidi kot NS3-serin proteazni inhibitorji virusa hepatitisa C |
US7244721B2 (en) | 2000-07-21 | 2007-07-17 | Schering Corporation | Peptides as NS3-serine protease inhibitors of hepatitis C virus |
AR029851A1 (es) | 2000-07-21 | 2003-07-16 | Dendreon Corp | Nuevos peptidos como inhibidores de ns3-serina proteasa del virus de hepatitis c |
AU2001282871A1 (en) * | 2000-08-17 | 2002-02-25 | Eli Lilly And Company | Antithrombotic agents |
WO2002030462A2 (en) | 2000-10-13 | 2002-04-18 | Curis, Inc. | Hedgehog antagonists, methods and uses related thereto |
US6376514B1 (en) | 2000-10-17 | 2002-04-23 | The Procter & Gamble Co. | Substituted six-membered heterocyclic compounds useful for treating multidrug resistance and compositions and methods thereof |
FR2816838B1 (fr) * | 2000-11-17 | 2004-12-03 | Oreal | Utilisation de derives de l'acide 2-oxothiazolidine- 4-carboxylique comme agents prodesquamants |
ATE409181T1 (de) | 2001-05-08 | 2008-10-15 | Univ Yale | Proteomimetische verbindungen und verfahren |
CA2462200A1 (en) | 2001-08-10 | 2003-02-20 | Palatin Technologies, Inc. | Peptidomimetics of biologically active metallopeptides |
WO2003062228A1 (en) | 2002-01-23 | 2003-07-31 | Schering Corporation | Proline compounds as ns3-serine protease inhibitors for use in treatment of hepatites c virus infection |
EP1480999A2 (en) | 2002-02-08 | 2004-12-01 | Idun Pharmaceuticals | (substituted)acyl dipeptidyl inhibitors of the ice/ced-3 family of cysteine proteases |
BR0312408A (pt) * | 2002-07-02 | 2005-04-19 | Novartis Ag | Inibidores de peptìdeo de ligação de proteìna smac a inibidor de apoptose de proteìnas (iap) |
AU2003265853A1 (en) | 2002-08-29 | 2004-03-19 | Curis, Inc. | Hedgehog antagonists, methods and uses related thereto |
AU2003299901A1 (en) * | 2002-10-04 | 2004-05-04 | Merck And Co., Inc. | Thrombin inhibitors |
AU2003302084A1 (en) | 2002-11-15 | 2004-06-15 | Bristol-Myers Squibb Company | Open chain prolyl urea-related modulators of androgen receptor function |
BR0316488A (pt) * | 2002-11-25 | 2005-10-11 | Zealand Pharma As | Métodos para modular uma comunicação de junção lacunar em uma população de células, e para tratar um paciente tendo ou sob risco de desenvolver uma condição patológica envolvendo comunicação de junção lacunar deficiente, uso de um peptìdeo, e, composição farmacêutica |
MXPA05010444A (es) | 2003-04-03 | 2005-11-04 | Merck Patent Gmbh | Compuestos de carbonilo. |
WO2004099134A2 (en) | 2003-05-05 | 2004-11-18 | Prosidion Ltd. | Glutaminyl based dp iv-inhibitors |
CN103145715B (zh) | 2003-10-14 | 2016-08-03 | F·霍夫曼-罗须公司 | 作为hcv复制抑制剂的巨环羧酸和酰基磺酰胺 |
CN1528745A (zh) | 2003-10-21 | 2004-09-15 | 山东大学 | 吡咯烷类基质金属蛋白酶抑制剂及其制备方法 |
US7507760B2 (en) | 2004-01-22 | 2009-03-24 | Neuromed Pharmaceuticals Ltd. | N-type calcium channel blockers |
WO2005085197A1 (en) | 2004-02-27 | 2005-09-15 | Schering Corporation | Cyclobutenedione groups-containing compounds as inhibitors of hepatitis c virus ns3 serine protease |
SI2573068T1 (sl) * | 2004-03-15 | 2015-03-31 | Janssen Pharmaceutica N.V. | Postopek za pripravo intermediatov spojin, ki so uporabne kot modulatorji opioidnega receptorja |
WO2005095403A2 (en) | 2004-03-30 | 2005-10-13 | Intermune, Inc. | Macrocyclic compounds as inhibitors of viral replication |
US7511062B2 (en) * | 2004-05-18 | 2009-03-31 | Schering Corporation | Substituted 2-quinolyl-oxazoles useful as PDE4 inhibitors |
EP1604977A1 (en) * | 2004-06-02 | 2005-12-14 | Faust Pharmaceuticals | CIS pyrrolidinyl derivatives and their uses |
PL1778702T3 (pl) | 2004-07-16 | 2011-12-30 | Gilead Sciences Inc | Związki przeciwwirusowe |
US7820699B2 (en) | 2005-04-27 | 2010-10-26 | Hoffmann-La Roche Inc. | Cyclic amines |
EP1943257A2 (en) | 2005-05-19 | 2008-07-16 | Genentech, Inc. | Fibroblast activation protein inhibitor compounds and methods |
PT1966130E (pt) * | 2005-12-23 | 2014-01-30 | Zealand Pharma As | Compostos miméticos de lisina modificados |
US20080188545A1 (en) | 2006-12-21 | 2008-08-07 | Alimardanov Asaf R | Synthesis of pyrrolidine compounds |
-
2006
- 2006-12-21 PT PT68491521T patent/PT1966130E/pt unknown
- 2006-12-21 CN CN201210106810.6A patent/CN102690221B/zh active Active
- 2006-12-21 CN CN2006800518550A patent/CN101336229B/zh active Active
- 2006-12-21 DK DK06849152.1T patent/DK1966130T3/da active
- 2006-12-21 SG SG201102116-9A patent/SG170767A1/en unknown
- 2006-12-21 BR BRPI0620436A patent/BRPI0620436B8/pt active IP Right Grant
- 2006-12-21 CA CA2634743A patent/CA2634743C/en active Active
- 2006-12-21 EP EP11166328.2A patent/EP2386539B1/en active Active
- 2006-12-21 NZ NZ569293A patent/NZ569293A/en not_active IP Right Cessation
- 2006-12-21 ES ES06849152.1T patent/ES2443242T3/es active Active
- 2006-12-21 KR KR1020087018182A patent/KR101397915B1/ko not_active IP Right Cessation
- 2006-12-21 EP EP06849152.1A patent/EP1966130B1/en active Active
- 2006-12-21 PL PL06849152T patent/PL1966130T3/pl unknown
- 2006-12-21 JP JP2008547546A patent/JP5473334B2/ja active Active
- 2006-12-21 AU AU2006332945A patent/AU2006332945C1/en active Active
- 2006-12-21 WO PCT/US2006/048790 patent/WO2007078990A2/en active Application Filing
- 2006-12-21 UA UAA200808527A patent/UA96283C2/uk unknown
- 2006-12-21 SI SI200631729T patent/SI1966130T1/sl unknown
- 2006-12-21 RU RU2008126246/04A patent/RU2494095C2/ru active
- 2006-12-21 US US11/643,192 patent/US7622496B2/en active Active
- 2006-12-22 PE PE2006001691A patent/PE20070849A1/es not_active Application Discontinuation
- 2006-12-22 TW TW095148422A patent/TWI411597B/zh active
- 2006-12-26 AR ARP060105793A patent/AR058748A1/es not_active Application Discontinuation
-
2008
- 2008-06-19 CR CR10089A patent/CR10089A/es not_active Application Discontinuation
- 2008-06-20 HN HN2008000957A patent/HN2008000957A/es unknown
- 2008-06-20 GT GT200800123A patent/GT200800123A/es unknown
- 2008-06-23 IL IL192395A patent/IL192395A/en not_active IP Right Cessation
- 2008-07-18 EC EC2008008633A patent/ECSP088633A/es unknown
-
2009
- 2009-03-05 HK HK09102143.3A patent/HK1121438A1/xx not_active IP Right Cessation
- 2009-10-30 US US12/610,172 patent/US8026272B2/en active Active
-
2011
- 2011-09-16 US US13/234,956 patent/US8431540B2/en active Active
-
2013
- 2013-04-01 US US13/854,423 patent/US20130225644A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ECSP088633A (es) | Compuestos miméticos de lisina modificados | |
ATE511502T1 (de) | Arylpropionamid-, arylacrylamid-, arylpropinamid- oder arylmethylharnstoffanaloge als faktor-xia- inhibitoren | |
DE502006007967D1 (de) | Wirkstoffkombinationen | |
EA201170703A1 (ru) | Производные адамантилбензамида | |
DE502006008090D1 (de) | Wirkstoffkombinationen | |
UY31038A1 (es) | Compuestos | |
DE602006015573D1 (de) | Bipolarplatte | |
AT501832A3 (de) | Lageranordnung | |
SG129432A1 (en) | Automated generation of multi-dimensional structure activity and structure property relationships | |
DE502005005693D1 (de) | Unterkühlte Horizontalkryostatanordnung | |
DE502006002413D1 (de) | Flechtvorrichtung | |
DK1681479T3 (da) | Lejearrangement | |
FI20055646A (fi) | Työväline kuormien käsittelyyn | |
FI20050972A0 (fi) | Hakarautajärjestely | |
RS53014B (en) | 4R, 5S-ENANTIOMER 2- (5-METHYL-2-OXO-4-PHENYL-PYROLIDIN-1-IL) -ACETAMIDE WITH NOOTROPIC ACTIVITY | |
NO20081069L (no) | Dynamisk, anvendelsesutvidende teknologi | |
ES1060307Y (es) | Canalizacion con fijacion desplazable | |
FR2892698B1 (fr) | Quille active | |
ITRN20050016U1 (it) | Struttura combinata. | |
ES1062032Y (es) | Escenario movil | |
AT502273A3 (de) | Tisch | |
UY3524Q (es) | Refugio peatonal con panel lateral | |
UY3525Q (es) | Refugio peatonal economico | |
ITBO20050501A1 (it) | Sedia da stiro | |
TH92397B (th) | โต๊ะทำงาน |